Partnership / Collaboration · GCC · Announced 15 Jun 2026
Glaxo Saudi Arabia → AJA Pharma
AJA Pharma, a Saudi Chemical Holding subsidiary, signed a three-year non-exclusive agreement to provide medical marketing services for GSK's pharmaceutical products in Saudi Arabia, paid as a share of GSK's Saudi sales.
Parties: Glaxo Saudi Arabia (GSK) (Saudi Arabia) → AJA Pharma (Saudi Arabia)
- Deal type
- Partnership / Collaboration
- Value
- Undisclosed
- Territory
- Saudi Arabia
- Therapeutic area
- Multi-therapy
- Asset
- GSK pharmaceutical portfolio (products not named)
- Announced
- 15 Jun 2026
Our analysis
Why this matters
AJA Pharmaceutical Industries (AJA Pharma), a subsidiary of Tadawul-listed Saudi Chemical Holding, signed a non-exclusive agreement with Glaxo Saudi Arabia Limited (GSK) on 15 June 2026 to provide medical marketing services for a wide range of GSK pharmaceutical products in Saudi Arabia, using AJA's medical field teams. The term is three years with an option to renew. Consideration is a percentage of GSK's Saudi sales, plus performance indicators and operational targets, and Saudi Chemical expects the annual value to be below 5% of group revenues. Financial impact was expected from Q3 2026.
A global originator contracting out field promotion to a local manufacturer is a sign of where multinational cost structures are heading in the Gulf. For CFOs, it turns a fixed sales-force cost into a variable, sales-linked fee.
The full analysis is free to read with a work email on this page.